Cyclin i correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 217-222

  Cybulski, Marek ^a   Jarosz, Bozena ^a   Nowakowski, Andrzej ^a,c   Jeleniewicz, Witold ^a   Seroczyński, Przemysław ^b   Mazurek Kociubowska, Magdalena ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b ASSECO SA   (Poland)

^c MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Angiogenesis; Cyclin I; Ovarian cancer; Prognostic factors; Survival; VEGFR 2

Indexed keywords

CYCLIN I; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; CYCLIN I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84865688091     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.06.038     Document Type: Article

References (35)

1. U.S. Cancer Statistics Working Group United States cancer statistics: 1999-2007 incidence and mortality web-based report 2010 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute Atlanta Available at: www.cdc.gov/uscs. Accessed March 14 (2012).
2. U.A. Matulonis Bevacizumab and its use in epithelial ovarian cancer Future Oncol 7 2011 365 379
3. C. Cordon-Cardo Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia Am J Pathol 147 1995 545 560
4. S.V. Griffin, J.P. Olivier, J.W. Pippin, J.M. Roberts, and S.J. Shankland Cyclin I protects podocytes from apoptosis J Biol Chem 281 2006 28048 28057
5. M.R. Jensen, T. Audolfsson, V.M. Factor, and S.S. Thorgeirsson In vivo expression and genomic organization of the mouse cyclin I gene (Ccni) Gene 256 2000 59 67
6. T. Nakamura, R. Sanokawa, Y.F. Sasaki, D. Ayusawa, M. Oishi, and N. Mori Cyclin I: a new cyclin encoded by a gene isolated from human brain Exp Cell Res 221 1995 534 542
7. Z.L. Sun, Y. Zhu, F.Q. Wang, R. Chen, T. Peng, and Z.N. Fan Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers Biochim Biophys Acta 1774 2007 764 771
8. G. Landberg, K. Nilsson, K. Jirström, L. Rydén, R. Kitching, and A.M. Burger Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression Breast Cancer Res Treat 89 2005 313 316
9. M. Shibuya Tyrosine kinase receptor flt/VEGFR family: its characterization related to angiogenesis and cancer Genes Cancer 1 2010 1119 1123
10. I. Sher, S.A. Adham, J. Petrik, and B.L. Coomber Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis Int J Cancer 124 2009 553 561
11. W.A. Spannuth, A.M. Nick, N.B. Jennings, G.N. Armaiz-Pena, L.S. Mangala, and C.G. Danes Functional significance of VEGFR-2 on ovarian cancer cells Int J Cancer 124 2009 1045 1053
12. B. Wang, P.T. Kaumaya, and D.E. Cohn Immunization with synthetic VEGF peptides in ovarian cancer Gynecol Oncol 119 2010 564 570
13. K.R. Lee, F.A. Tavassoli, J. Prat, M. Dietel, D.J. Gersell, and A.I. Karseladze Surface epithelial-stromal tumours F.A. Tavassoli, P. Devillee, World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs 2003 IARC Press Lyon 113 145
14. E.L. Eisenhauer, N.R. Abu-Rustum, Y. Sonoda, C. Aghajanian, R.R. Barakat, and D.S. Chi The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer Gynecol Oncol 108 2008 276 281
15. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
16. A. Seth, R. Kitching, G. Landberg, J. Xu, J. Zubovits, and A.M. Burger Gene expression profiling of ductal carcinomas in situ and invasive breast tumors Anticancer Res 23 2003 2043 2051
17. P.T. Brinkkoetter, P. Olivier, J.S. Wu, S. Henderson, R.D. Krofft, and J.W. Pippin Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells J Clin Invest 119 2009 3089 3101
18. Y.L. Ge, J.Y. Zhang, X. Zhang, L. Hou, Q. Li, and M.L. Xue Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells Mol Med Report 2 2009 121 127
19. S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, and M. Kanemura Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model Clin Cancer Res 14 2008 7781 7789
20. S. Machida, Y. Saga, Y. Takei, I. Mizuno, T. Takayama, and T. Kohno Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68) Int J Cancer 114 2005 224 229
21. W.M. Merritt, A.M. Nick, A.R. Carroll, C. Lu, K. Matsuo, and M. Dumble Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer Mol Cancer Ther 9 2010 985 995
22. M. Zillhardt, S.M. Park, I.L. Romero, K. Sawada, A. Montag, and T. Krausz Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis Clin Cancer Res 17 2011 4042 4051
23. N. Nishida, H. Yano, K. Komai, T. Nishida, T. Kamura, and M. Kojiro Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma Cancer 101 2004 1364 1374
24. G. Xia, S.R. Kumar, D. Hawes, J. Cai, L. Hassanieh, and S. Groshen Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol 175 2006 1245 1252
25. V. Kaushal, P. Mukunyadzi, R.A. Dennis, E.R. Siegel, D.E. Johnson, and M. Kohli Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease Clin Cancer Res 11 2005 584 593
26. S.J. An, Q. Nie, Z.H. Chen, Q.X. Lin, Z. Wang, and Z. Xie KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer J Cancer Res Clin Oncol 133 2007 635 642
27. B.K. Linderholm, H. Hellborg, U. Johansson, L. Skoog, and J. Lehtiö Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer Breast Cancer Res Treat 125 2011 457 465
28. B. Paule, E. Deslandes, S.P. Le Mouel, L. Bastien, M.P. Podgorniak, and Y. Allory Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma Int J Biol Markers 25 2010 112 115
29. C. Rodríguez-Antona, J. Pallares, C. Montero-Conde, L. Inglada-Pérez, E. Castelblanco, and I. Landa Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr Relat Cancer 17 2010 7 16
30. J.M. Mehnert, M.M. McCarthy, L. Jilaveanu, K.T. Flaherty, S. Aziz, and R.L. Camp Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays Hum Pathol 41 2010 375 384
31. D. Klasa-Mazurkiewicz, M. Jarza̧b, T. Milczek, B. Lipińska, and J. Emerich Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients Pol J Pathol 62 2011 31 40
32. S. Andersen, T. Donnem, S. Al-Saad, K. Al-Shibli, L.T. Busund, and R.M. Bremnes Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy J Thorac Oncol 4 2009 463 471
33. T. Klatte, D.B. Seligson, J. LaRochelle, B. Shuch, J.W. Said, and S.B. Riggs Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy Cancer Epidemiol Biomarkers Prev 18 2009 894 900
34. H.S. Nimeiri, A.M. Oza, R.J. Morgan, G. Friberg, K. Kasza, and L. Faoro Chicago Phase II Consortium; PMH Phase II Consortium; California Phase II Consortium. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 110 2008 49 55
35. M. Pölcher, M. Eckhardt, C. Coch, M. Wolfgarten, K. Kübler, and G. Hartmann Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer Cancer Chemother Pharmacol 66 2010 203 207